Low Risk of Melanoma-Specific Mortality Seen in Patients With MIS
Source: AJMC, June 2023
The incidence rate of melanoma in situ (MIS) has sharply risen since 1975.
Patients with melanoma in situ (MIS) have an increased but low risk of melanoma-specific mortality, new results of a cohort study show.
Findings published in JAMA Dermatology also revealed these individuals live longer than the general population, “suggesting that there is significant detection of low-risk disease among health-seeking individuals,” authors wrote.